Healthcare
STRATA Skin Sciences, Inc.(SSKN)
Live Price
Offline$0.14
+0.00% today
1Y Change
-93.94%
Window
Jun 20, 2025 โ Jun 18, 2026
- Market Cap
- โ
- Revenue Growth
- -8.5%
- EPS Growth
- -419.2%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 20, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
STRATA Skin Sciences, Inc. (SSKN) is a Healthcare stock with listed on OTC. The stock last traded around $0.14 and down 93.9% across the available one-year price window (Jun 20, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -8.5%, EPS growth of -419.2%, a dividend yield of 0.0%. What stands out right now is revenue -8.5%, EPS -419.2%, free cash flow -194.3% with operating margin -19.7% and ROIC -31.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SSKN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-8.5% vs +7.6% peer median
Operating Margin
Below sector median
-19.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -8.5% and EPS is at -419.2%, with operating margin around -19.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -14.9% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -18.8% | -18.8% | -18.8% |
2026 Mar 25, 2026 | +150.0% | +0.0% | -12.0% | -36.0% |
2025 Nov 13, 2025 | -38.5% | -10.5% | -13.8% | -6.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SSKN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SSKN Max Drawdown
-95.76%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SSKN and SPY.
Company Overview
STRATA Skin Sciences, Inc.
Other OTC
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
- Leadership
- Dolev Rafaeli
- IPO Date
- Nov 3, 2005
- Employees
- 106
- Street Address
- 5 Walnut Grove Drive
- Mailing
- Horsham, PA, 19044
- Region
- Horsham, PA, US
- Reporting Currency
- USD
- Investor Line
- 215 619 3200
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.0
- Price/Book
- 0.3
Growth
- Revenue
- -8.5%
- EPS
- -419.2%
- Free Cash Flow
- -194.3%
Profitability
- Gross Margin
- 57.8%
- Operating Margin
- -19.7%
- Net Margin
- -21.1%
- ROE
- -360.3%
- ROIC
- -31.7%
Balance Sheet
- Debt/Equity
- 5.59
- Current Ratio
- 0.58
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.